A Phase 4 interventional study of Comirnaty Injectable Product and Sodium Chloride 0.9% Inj in Diabetes Mellitus, Type 1, sponsored by Technical University of Munich. Recruiting at 9 sites in 5 countries. Open to participants aged 3 Months to 4 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Technical University of Munich · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 30 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.
Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one is the 2nd largest by planned enrollment of the 260 interventional ones that give a count, is one of 8 that started in 2024, is one of 11 in phase 4, reaches primary completion later than 15 of the 29 other live ones, and was the 269th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:
Bionime Corporation · Sites in Germany
Ages 18+ · Women only
Sam Chun Dang Pharm. Co. Ltd. · Sites in Germany
Ages 18–64 · Men only
Novo Nordisk A/S · Sites in Germany
Ages 18–55
Sanofi · Sites in Germany, United States, Israel and 1 more country
Sanofi · Sites in Germany, Belgium, France and 3 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 3 Months to 4 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
294 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 112 · Phase 2 41 · Phase 3 64 · Phase 4 11
First in 1997; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,252 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 61 across the 260 interventional studies, 1,000 across the 33 observational. Of the 255 that completed or were terminated, 82 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 294 have an industry lead sponsor. The 10 most frequent:
Technical University of Munich is the lead sponsor of 323 studies on the registry; 61 are open to participants now.
Technical University of Munich has 6 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 1 with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT07160816Novo Nordisk A/SA Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar | 2027-01-20 |
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or placebo from age 6 months.
The study is an investigator initiated, randomized, controlled, multicentre, multinational, primary prevention trial for children at increased risk of type 1 diabetes.
The primary objective is to determine whether vaccination of children with elevated genetic risk for type 1 diabetes against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in childhood.
Secondary objectives are:
Further exploratory objectives are described in the study protocol.
Study participants will be identified through an ongoing study screening for genetic risk of type 1 diabetes using a polygenic risk score (NCT03316261).
Eligible participants will be enrolled at age 3.00 to 4.00 months (baseline visit).
Randomization to vaccine or placebo will occur at age 6.00 to 7.00 months at visit 2. Consent will be obtained by the custodial parents prior to enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comirnaty® 3 µg Omicron XBB.1.5 or future new variant developments replacing current Comirnaty vaccines for children Suspension for injection, for intramuscular use 1. st dose at age 6.0 to 7.0 months 2. nd dose at least 3 weeks through to 6 weeks after 1st dose 3. rd dose at least 8 weeks after 2nd dose (around age 8.5 to 11 months) Dose adjustment in case of COVID-19 infection.
Drug: Comirnaty Injectable Product
0.9 % Sodium Chloride Solution (saline) for intramuscular injection Dosing: three doses 1. st dose at age 6.0 to 7.0 months 2. nd dose at least 3 weeks through to 6 weeks after 1st dose 3. rd dose at least 8 weeks after 2nd dose (around age 8.5 to 11 months)
Drug: Sodium Chloride 0.9% Inj
Vaccination
Also known as: Comirnaty 3µg/dose for children for 6 month - 4 years
Vaccination
Also known as: Solution for Injection
Persistent confirmed islet autoantibodies or type 1 diabetes
The primary outcome is the elapsed time from first vaccination to the development of persistent confirmed islet autoantibodies or type 1 diabetes.
Time frame: Through study completion, up to 6 years
Persistent confirmed multiple islet autoantibodies
Elapsed time from first vaccination to persistent confirmed multiple islet autoantibodies;
Time frame: Through study completion, up to 6 years
Type 1 diabetes
Elapsed time from first vaccination to type 1 diabetes.
Time frame: Through study completion, up to 6 years
Persistent confirmed transglutaminase autoantibodies
Elapsed time from first vaccination to the development of persistent confirmed transglutaminase autoantibodies.
Time frame: Through study completion, up to 6 years
Started May 2024 (actual). Primary completion is estimated for Oct 2027, 41 months after the start.
Of 62 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 41 months is above that.
Counting every sponsor, half of 74 studies reached it within 22 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine
Technical University of Munich →